Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
AstraZeneca, Merck's Lynparza scores speedy review in blockbuster ovarian cancer market
Last month, AstraZeneca and Merck’s Lynparza posted big-time ovarian cancer data, and regulators are taking note.
WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation
Antimicrobial resistance is a major threat to health and human development, affecting our ability to treat a range of infections.
Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE
AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin).
First Human Clinical Trial of HIV Drug Gammora Offers Potential Cure
Investigational Medicinal Product (IMP) Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which is responsible for inserting the virus's genetic material into ...
Mylan and Theravance's COPD treatment gets FDA approval
(Reuters) - Theravance Biopharma Inc and partner Mylan NV on Friday won U.
New drug options, risk factors added to U.S. heart guidelines
(Reuters) - Updated U.
Fluorescent marker can help guide surgeons to remove dangerous brain tumour cells more accurately
A chemical that highlights tumour cells has been used by surgeons to help spot and safely remove brain cancer in a trial presented by a University of Bristol academic at the 2018 NCRI Cancer Conferenc...
Recro Pharma expands CDMO business in Georgia
Recro Pharma was granted a March 2019 PDUFA date for its non-opioid pain drug after providing the FDA with additional data and answering manufacturing questions raised in a complete response letter.
Hikma to produce injectables in Vietnam with deal for Medlac Pharma Italy
Hikma Pharmaceuticals has established itself as a top sterile injectables manufacturer in the U.
AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
Mallinckrodt’s Niemann-Pick Type C drug fails to hit trial target
UK-based Mallinckrodt has revealed that its experimental therapy for Niemann-Pick Type C failed to hit targets in a recently completed registration trial.
Mylan overhaul of West Virginia plant has a ways to go
While Mylan’s third quarter results impressed analysts, the generics drugmaker is still dealing with some significant manufacturing issues, some of them not of its own making.
407
408
409
410
411
412
413
414
415
